Reducing mortality in newly diagnosed standard-risk acute promyelocytic leukemia in elderly patients treated with arsenic trioxide requires major reduction of chemotherapy: a report by the French Belgian Swiss APL group (APL 2006 trial)

• Ramy Rahmé,
• Lionel Ades,
• Xavier Thomas,
• Agnès Guerci-Bresler,
• Arnaud Pigneux,
• Norbert Vey,
• Emmanuel Raffoux,
• Sylvie Castaigne,
• Olivier Spertini,
• Sebastian Wittnebel,
• Jean Pierre Marolleau,
• Gandhi Damaj,
• Dominique Bordessoule,
• Julie Lejeune,
• Sylvie Chevret,
• Pierre Fenaux

Affiliations

Ramy Rahmé

Hôpital Saint Louis, Université Paris Diderot, France

Lionel Ades

Hôpital Saint Louis, Université Paris Diderot, France

Xavier Thomas

Hospices Civils de Lyon, Département d’Hématologie, Centre Hospitalier Lyon-Sud, Pierre Bénite, France

Agnès Guerci-Bresler

Hematology Department, Nancy University Hospital, France

Arnaud Pigneux

Hematology Department, Bordeaux University Hospital, France

Norbert Vey

Institut Paoli Calmette, Marseille, France

Emmanuel Raffoux

Hôpital Saint Louis, Université Paris Diderot, France

Sylvie Castaigne

Hematology Department, Versailles University Hospital, France

Olivier Spertini

Hematology Department, University of Lausanne, CHUV, Switzerland

Sebastian Wittnebel

Deparment of Clinical and Experimental Hematology, Institut Jules Bordet (ULB), Brussels, Belgium

Jean Pierre Marolleau

Hematology Department, Amiens University Hospital, France

Gandhi Damaj

Hematology Department, Caen University Hospital, France

Dominique Bordessoule

Hematology Department, Limoges University Hospital, France

Julie Lejeune

Service de Biostatistique et Information médicale, Hôpital Saint Louis, Université Paris Diderot, France

Sylvie Chevret

Service de Biostatistique et Information médicale, Hôpital Saint Louis, Université Paris Diderot, France

Pierre Fenaux

Hôpital Saint Louis, Université Paris Diderot, France